Evidence map›Paper›PMID 38170396›Full record

ArticleJournal of endocrinological investigation2024

Competing risk nomogram and risk classification system for evaluating overall and cancer-specific survival in neuroendocrine carcinoma of the cervix: a population-based retrospective study.

J Liu, Y Lyu, Y He, J Ge, W Zou, S Liu, H Yang, J Li, K Jiang

Abstract read
In one paragraph

Article in Journal of endocrinological investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

J Liu *School of Basic Medical Sciences, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Y Lyu *Department of Obstetrics and Gynecology, Xijing Hospital of Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Y HeDepartment of Obstetrics and Gynecology, Xijing Hospital of Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
J GeDepartment of Obstetrics and Gynecology, Xijing Hospital of Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
W ZouDepartment of Obstetrics and Gynecology, Xijing Hospital of Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
S LiuDepartment of Obstetrics and Gynecology, Xijing Hospital of Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
H YangDepartment of Obstetrics and Gynecology, Xijing Hospital of Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
J LiDepartment of Obstetrics and Gynecology, Xijing Hospital of Fourth Military Medical University, Xi'an, 710032, Shaanxi, China. lijia219@yeah.net.
K JiangDepartment of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China. jiangkuo520@qq.com.ORCID http://orcid.org/0000-0002-3777-5411

Funding

National Natural Science Foundation of China 81702668National Natural Science Foundation of China 82172993National Natural Science Foundation of China 82273376Shaanxi Province key R&D Project 2023-YBSF-484
6 · The paper itself

Abstract

objectiveNeuroendocrine carcinoma of the cervix (NECC) is a rare malignancy with poor clinical prognosis due to limited therapeutic options. This study aimed to establish a risk-stratification score and nomogram models to predict prognosis in NECC patients.

methodsData on individuals diagnosed with NECC between 2000 and 2019 were retrieved from the Surveillance Epidemiology and End Results (SEER) database and then randomly classified into training and validation cohorts (7:3). Univariate and multivariate Cox regression analyses evaluated independent indicators of prognosis. Least absolute shrinkage and selection operator (LASSO) regression analysis further assisted in confirming candidate variables. Based on these factors, cancer-specific survival (CSS) and overall survival (OS) nomograms that predict survival over 1, 3, and 5 years were constructed. The receiver operating characteristic (ROC) curve, the concordance index (C-index), and the calibration curve estimated the precision and discriminability of the competing risk nomogram for both cohorts. Finally, we assessed the clinical value of the nomograms using decision curve analysis (DCA).

resultsData from 2348 patients were obtained from the SEER database. Age, tumor stage, T stage, N stage, chemotherapy, radiotherapy, and surgery predicted OS. Additionally, histological type was another standalone indicator of CSS prognosis. For predicting CSS, the C-index was 0.751 (95% CI 0.731 ~ 0.770) and 0.740 (95% CI 0.710 ~ 0.770) for the training and validation cohorts, respectively. Furthermore, the C-index in OS prediction was 0.757 (95% CI 0.738 ~ 0.776) and 0.747 (95% CI 0.718 ~ 0.776) for both cohorts. The proposed model had an excellent discriminative ability. Good accuracy and discriminability were also demonstrated using the AUC and calibration curves. Additionally, DCA demonstrated the high clinical potential of the nomograms for CSS and OS prediction. We constructed a corresponding risk classification system using nomogram scores. For the whole cohort, the median CSS times for the low-, moderate-, and high-risk groups were 59.3, 19.5, and 7.4 months, respectively.

conclusionNew competing risk nomograms and a risk classification system were successfully developed to predict the 1-, 3-, and 5-year CSS and OS of NECC patients. The models are internally accurate and reliable and may guide clinicians toward better clinical decisions and the development of personalized treatment plans.

Indexed as

Carcinoma, NeuroendocrineNomogramsSEER ProgramUterine Cervical NeoplasmsAdultAgedFemaleFollow-Up StudiesHumansMiddle AgedPrognosisRetrospective StudiesRisk AssessmentRisk FactorsROC CurveSurvival RateCancer-specific survivalCompeting riskNeuroendocrine carcinoma of the cervixNomogramOverall survivalRisk stratification

Identifiers

PMID38170396
PMCPMC11143030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.